INR 698.8
(3.55%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 5.7 Billion INR | 23.74% |
2022 | 4.6 Billion INR | -11.25% |
2021 | 5.19 Billion INR | 34.77% |
2020 | 3.85 Billion INR | 23.66% |
2019 | 3.11 Billion INR | 12.17% |
2018 | 2.77 Billion INR | 30.49% |
2017 | 2.12 Billion INR | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 1.66 Billion INR | 3.41% |
2024 Q1 | 1.6 Billion INR | 1.55% |
2023 Q1 | 1.32 Billion INR | -7.2% |
2023 Q4 | 1.58 Billion INR | 12.93% |
2023 Q3 | 1.4 Billion INR | -0.01% |
2023 Q2 | 1.4 Billion INR | 6.12% |
2023 FY | 5.7 Billion INR | 23.74% |
2022 Q4 | 1.42 Billion INR | 35.32% |
2022 Q3 | 1.05 Billion INR | -6.27% |
2022 Q2 | 1.12 Billion INR | 10.67% |
2022 Q1 | 1.01 Billion INR | -42.92% |
2022 FY | 4.6 Billion INR | -11.25% |
2021 Q2 | 1.47 Billion INR | 92.17% |
2021 FY | 5.19 Billion INR | 34.77% |
2021 Q1 | 769.42 Million INR | -40.65% |
2021 Q4 | 1.77 Billion INR | 51.77% |
2021 Q3 | 1.17 Billion INR | -20.87% |
2020 Q3 | 806.91 Million INR | 0.0% |
2020 FY | 3.85 Billion INR | 23.66% |
2020 Q4 | 1.29 Billion INR | 60.67% |
2019 FY | 3.11 Billion INR | 12.17% |
2018 FY | 2.77 Billion INR | 30.49% |
2017 FY | 2.12 Billion INR | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Biocon Limited | 147.55 Billion INR | 96.135% |
Blue Jet Healthcare Limited | 7.11 Billion INR | 19.847% |
Concord Biotech Limited | 9.98 Billion INR | 42.852% |
Dishman Carbogen Amcis Limited | 26.15 Billion INR | 78.195% |
Jubilant Ingrevia Limited | 41 Billion INR | 86.09% |
Lyka Labs Limited | 1.05 Billion INR | -442.526% |
Panacea Biotec Limited | 5.59 Billion INR | -2.003% |
Piramal Pharma Limited | 81.71 Billion INR | 93.02% |
SMS Lifesciences India Limited | 3.05 Billion INR | -86.421% |
Syngene International Limited | 34.88 Billion INR | 83.65% |
TAKE Solutions Limited | 656.08 Million INR | -769.36% |
Zota Health Care Limited | 1.8 Billion INR | -216.015% |